Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Operating Income (2017 - 2026)

Denali Therapeutics has reported Operating Income over the past 9 years, most recently at -$137.4 million for Q4 2025.

  • Quarterly Operating Income fell 5.79% to -$137.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$555.3 million through Dec 2025, down 13.95% year-over-year, with the annual reading at -$555.3 million for FY2025, 13.95% down from the prior year.
  • Operating Income was -$137.4 million for Q4 2025 at Denali Therapeutics, roughly flat from -$137.4 million in the prior quarter.
  • Over five years, Operating Income peaked at $170.5 million in Q2 2023 and troughed at -$145.6 million in Q1 2025.
  • The 5-year median for Operating Income is -$115.2 million (2023), against an average of -$93.8 million.
  • Year-over-year, Operating Income skyrocketed 377.59% in 2023 and then tumbled 168.39% in 2024.
  • A 5-year view of Operating Income shows it stood at -$77.1 million in 2021, then crashed by 36.6% to -$105.3 million in 2022, then dropped by 25.85% to -$132.6 million in 2023, then rose by 2.06% to -$129.8 million in 2024, then decreased by 5.79% to -$137.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Operating Income are -$137.4 million (Q4 2025), -$137.4 million (Q3 2025), and -$135.0 million (Q2 2025).